Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Day One Biopharmaceuticals (DAWN) Revenue (2024 - 2025)

Day One Biopharmaceuticals (DAWN) has disclosed Revenue for 2 consecutive years, with $53.7 million as the latest value for Q4 2025.

  • Quarterly Revenue rose 83.92% to $53.7 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $158.2 million through Dec 2025, up 20.6% year-over-year, with the annual reading at $158.2 million for FY2025, 20.6% up from the prior year.
  • Revenue for Q4 2025 was $53.7 million at Day One Biopharmaceuticals, up from $39.8 million in the prior quarter.
  • The five-year high for Revenue was $93.8 million in Q3 2024, with the low at $8.2 million in Q2 2024.